COLO 205

COLO 205细胞COLO 205人结肠癌细胞Cell line name COLO 205

Synonyms Colo 205; CoLo 205; COLO-205; Colo-205; COLO.205; Colo205; COLO205; Co 205; Colorado 205

Accession CVCL_0218

Resource Identification Initiative To cite this cell line use: COLO 205 (RRID:CVCL_0218)

Comments Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Part of: NCI-7 clinical proteomics reference material cell line panel.

Population: Caucasian.

Doubling time: 26.76 hours (PubMed=25944804); 25 hours (PubMed=25984343); 20-25 hours (CLS=300380); 23.8 hours (NCI-DTP=COLO 205).

Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=24755471; PubMed=25926053; PubMed=28683746; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795

PubMed=565251

Semple T.U., Quinn L.A., Woods L.K., Moore G.E.

Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model.

Cancer Res. 38:1345-1355(1978)

 

PubMed=6277475

Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E., Moseley J.M., Martin T.J.

Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.

Cancer Res. 42:1116-1119(1982)

 

PubMed=3629545; DOI=10.1016/0049-3848(87)90273-8

Scarlett J.D., Thurlow P.J., Connellan J.M., Louis C.J.

Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.

Thromb. Res. 46:715-726(1987)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

 

PubMed=7651727

Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Oncogene 11:647-652(1995)

 

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

 

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

 

PubMed=10051639; DOI=10.1073/pnas.96.5.2316; PMCID=PMC26781

Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M., Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J., Pignatelli M., Bodmer W.F.

Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells.

Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999)

 

PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3

Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.

Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.

Eur. J. Cancer 35:1724-1729(1999)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

 

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)